Switch theme
Sign up to access all valuation multiples
BioRegenx Inc is redefining health intelligence with new patented technologies and artificial intelligence. Its specialize in developing intellectual property (IP) and are engaged in regenerative biotherapeutics, anti-aging, artificial intelligence (AI) for healthcare and bioinformatics for public and private transportation. The primary focus involves acquiring or developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing extensive datasets.
1998
10
LTM Revenue n/a
LTM EBITDA n/a
$9.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioRegenx has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BioRegenx achieved revenue of $2.3M and an EBITDA of -$20.5M.
BioRegenx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioRegenx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $22K | $2.3M | XXX | XXX | XXX |
| Gross Profit | $42K | $22K | XXX | XXX | XXX |
| Gross Margin | 190% | 1% | XXX | XXX | XXX |
| EBITDA | -$0.6M | -$20.5M | XXX | XXX | XXX |
| EBITDA Margin | -2504% | -878% | XXX | XXX | XXX |
| Net Profit | -$0.1M | -$0.6M | XXX | XXX | XXX |
| Net Margin | -352% | -24% | XXX | XXX | XXX |
| Net Debt | $0.2M | $0.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, BioRegenx's stock price is $0.
BioRegenx has current market cap of $7.7M, and EV of $9.8M.
See BioRegenx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.8M | $7.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, BioRegenx has market cap of $7.7M and EV of $9.8M.
BioRegenx's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate BioRegenx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioRegenx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.8M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | XXX | XXX |
| P/E | -0.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -19.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioRegenx's NTM/LTM revenue growth is n/a
BioRegenx's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, BioRegenx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioRegenx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioRegenx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10421% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -878% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3589% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 250% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 351% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogstate | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| Impedimed | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioRegenx acquired XXX companies to date.
Last acquisition by BioRegenx was XXXXXXXX, XXXXX XXXXX XXXXXX . BioRegenx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioRegenx founded? | BioRegenx was founded in 1998. |
| Where is BioRegenx headquartered? | BioRegenx is headquartered in United States of America. |
| How many employees does BioRegenx have? | As of today, BioRegenx has 10 employees. |
| Is BioRegenx publicy listed? | Yes, BioRegenx is a public company listed on PINX. |
| What is the stock symbol of BioRegenx? | BioRegenx trades under BRGX ticker. |
| Who are competitors of BioRegenx? | Similar companies to BioRegenx include e.g. Beamtree, Cogstate, Echo IQ, Impedimed. |
| What is the current market cap of BioRegenx? | BioRegenx's current market cap is $7.7M |
| What is the current revenue growth of BioRegenx? | BioRegenx revenue growth between 2023 and 2024 was 10421%. |
| Is BioRegenx profitable? | Yes, BioRegenx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
